NASDAQ
5.20USD
-0.12 (-2.26%)
We have scored 16 news catalysts on RxSight, Inc. (RXST) over the past 12 months. The biggest single-day move next to one of them came Jan 1, 2026, when RXST closed −3.4%: “INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST”. Coverage across the window leans negative (average ticker sentiment −0.45). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
215.3M
P/E
—
EPS
—
Beta
1.16
52W range
4.48-13.22
Day range
5.17–5.36
Open
5.24
Prev close
5.32
Volume
1.1M
Avg volume
1M
Dividend
0.00
IPO
2021-07-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about RxSight, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for RXST: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
